- Enterprise.
- Not disclosed
- Not disclosed
- —
- —
- DE
AI for IHC breast/colon cancer scoring.
Free tier available.
IHC breast/colon scoring. Integrated with PathAI and Lumea.
What it costs
Free tier only; no paid plans publicly disclosed.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Plan | — | — | Enterprise. |
Source: vendor pricing page. Verified May 23, 2026.
What the literature says
2 peer-reviewed studies indexed on PubMed evaluate Mindpeak in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.
- Analytical Comparison of Commonly Used Laboratory-Developed Tests for the Assessment of Ki-67 in Breast Carcinoma With a Food and Drug Administration-Approved Benchmark.
- Badve S, White JS, Sapunar F, et al.· Mod Pathol· 2025Observational
- Ki-67 immunohistochemistry (IHC), a commonly used assay for breast cancer risk prognostication, has significant interlaboratory heterogeneity. This study assessed the impact of antibody clones by comparing the Ki-67 IHC MIB-1 pharmDx assay (Dako Omnis; Agilent Technologies) with clones MIB-1 (Dako Autostainer Link 48 platform), K2 (Leica BOND-III platform), and 30-9 (Ventana BenchMark ULTRA platform) used in Ki-67 laboratory-developed IHC tests. Breast cancer tissue microarrays were processed and stained in 2 central laboratories per the manufacturer's instructions. Digitized images were asse…
- Ki-67 Quantification in Breast Cancer by Digital Imaging AI Software and its Concordance with Manual Method.
- Zehra T, Shams M, Ahmad Z, et al.· J Coll Physicians Surg Pak· 2023
- To validate the concordance of automated detection of Ki67 in digital images of breast cancer with the manual eyeball / hotspot method. Descriptive study. Place and Duration of the Study: Jinnah Sindh Medical University, Karachi, from 1st January to 15th February 2022. Glass slides of cases diagnosed as invasive ductal carcinoma (IDC) were obtained from the Agha Khan Medical University Hospital, selected retrospectively and randomly from 60 patients. They were stained with the Ki67 antibody. An expert pathologist evaluated the Ki67 index in the hotspot fields using eyeball method. Digital ima…
Other pathology
See the full pathology ranking
Tempus Digital Pathology
by Tempus AI
Paige Predict 123-biomarker pan-cancer suite (Tempus acquired Paige 2025).
Enterprise + per-test.|FDA 510(k) / CE-IVDRPathAI AISight
by PathAI
Open IMS platform with AISight Dx + biopharma diagnostic services.
Enterprise.
Proscia Concentriq
by Proscia
Most-considered IMS platform, used by 16/20 top pharma.
Enterprise.Ibex Medical Analytics
by Ibex
Most-deployed AI pathology platform globally.
Enterprise.
